IgG from Epstein-Barr virus infectious mononucleosis patients inhibits interleukin-2 production.
Patients with Epstein-Barr virus (EBV)-associated dissorders usually demonstrate evidence of immunosupression during active disease. Sera of some patients with EBV-induced infectious mononucleosis (IM), contain an IgG-blocking factor (IM-IgG) which inhibits in vitro cell-mediated immune responses and which we postulate plays an important role in viral immunosuppression. We had shown earlier that Isoprinosine (an immunostimulator) has a counterinhibitory effect on this IM-IgG activity. Here we describe evidence showing for the first time that the immunosuppressive activity of IM-IgG is aimed at inhibition of interleukin-2 (IL-2) synthesis and does not affect IL-2 receptors.
D001667:Binding, Competitive; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology*; D007165:Immunosuppression Therapy; D066298:In Vitro Techniques; D007244:Infectious Mononucleosis / Q000276:immunology*; D007376:Interleukin-2 / Q000096:biosynthesis*; D007694:Killer Cells, Natural / Q000276:immunology; D008213:Lymphocyte Activation; D010835:Phytohemagglutinins / Q000494:pharmacology
D007074:Immunoglobulin G; D007376:Interleukin-2; D010835:Phytohemagglutinins